176 related articles for article (PubMed ID: 11202485)
1. Beryllium disease.
Saltini C; Amicosante M
Am J Med Sci; 2001 Jan; 321(1):89-98. PubMed ID: 11202485
[TBL] [Abstract][Full Text] [Related]
2. Beryllium presentation to CD4+ T cells is dependent on a single amino acid residue of the MHC class II beta-chain.
Bill JR; Mack DG; Falta MT; Maier LA; Sullivan AK; Joslin FG; Martin AK; Freed BM; Kotzin BL; Fontenot AP
J Immunol; 2005 Nov; 175(10):7029-37. PubMed ID: 16272364
[TBL] [Abstract][Full Text] [Related]
3. Role of the HLA-DP Glu 69 and the TNF-alpha TNF-alpha 2 gene markers in susceptibility to beryllium hypersensitivity.
Rogliani P; Amicosante M; Berretta F; Dotti C; Bocchino M; O'Donnell KM; Saltini C
Int J Immunopathol Pharmacol; 2004; 17(2 Suppl):3-10. PubMed ID: 15345185
[TBL] [Abstract][Full Text] [Related]
4. HLA-DP-unrestricted TNF-alpha release in beryllium-stimulated peripheral blood mononuclear cells.
Amicosante M; Berretta F; Franchi A; Rogliani P; Dotti C; Losi M; Dweik R; Saltini C
Eur Respir J; 2002 Nov; 20(5):1174-8. PubMed ID: 12449171
[TBL] [Abstract][Full Text] [Related]
5. Beryllium presentation to CD4+ T cells underlies disease-susceptibility HLA-DP alleles in chronic beryllium disease.
Fontenot AP; Torres M; Marshall WH; Newman LS; Kotzin BL
Proc Natl Acad Sci U S A; 2000 Nov; 97(23):12717-22. PubMed ID: 11050177
[TBL] [Abstract][Full Text] [Related]
6. Immunogenetic basis of environmental lung disease: lessons from the berylliosis model.
Saltini C; Amicosante M; Franchi A; Lombardi G; Richeldi L
Eur Respir J; 1998 Dec; 12(6):1463-75. PubMed ID: 9877510
[TBL] [Abstract][Full Text] [Related]
7. Major histocompatibility locus genetic markers of beryllium sensitization and disease.
Saltini C; Richeldi L; Losi M; Amicosante M; Voorter C; van den Berg-Loonen E; Dweik RA; Wiedemann HP; Deubner DC; Tinelli C
Eur Respir J; 2001 Oct; 18(4):677-84. PubMed ID: 11716174
[TBL] [Abstract][Full Text] [Related]
8. Recombinant HLA-DP2 binds beryllium and tolerizes beryllium-specific pathogenic CD4+ T cells.
Fontenot AP; Keizer TS; McCleskey M; Mack DG; Meza-Romero R; Huan J; Edwards DM; Chou YK; Vandenbark AA; Scott B; Burrows GG
J Immunol; 2006 Sep; 177(6):3874-83. PubMed ID: 16951350
[TBL] [Abstract][Full Text] [Related]
9. Beryllium-induced tumor necrosis factor-alpha production by CD4+ T cells is mediated by HLA-DP.
Sawyer RT; Parsons CE; Fontenot AP; Maier LA; Gillespie MM; Gottschall EB; Silveira L; Newman LS
Am J Respir Cell Mol Biol; 2004 Jul; 31(1):122-30. PubMed ID: 14975942
[TBL] [Abstract][Full Text] [Related]
10. Chronic beryllium disease: T cell recognition of a metal presented by HLA-DP.
Fontenot AP; Newman LS; Kotzin BL
Clin Immunol; 2001 Jul; 100(1):4-14. PubMed ID: 11414740
[No Abstract] [Full Text] [Related]
11. HLA-DPB1 glutamate 69: a genetic marker of beryllium disease.
Richeldi L; Sorrentino R; Saltini C
Science; 1993 Oct; 262(5131):242-4. PubMed ID: 8105536
[TBL] [Abstract][Full Text] [Related]
12. Linking genetic susceptibility and T cell activation in beryllium-induced disease.
Falta MT; Bowerman NA; Dai S; Kappler JW; Fontenot AP
Proc Am Thorac Soc; 2010 May; 7(2):126-9. PubMed ID: 20427584
[TBL] [Abstract][Full Text] [Related]
13. Chronic beryllium disease: immune-mediated destruction with implications for organ-specific autoimmunity.
Fontenot AP; Kotzin BL
Tissue Antigens; 2003 Dec; 62(6):449-58. PubMed ID: 14617028
[TBL] [Abstract][Full Text] [Related]
14. T cell recognition in chronic beryllium disease.
Amicosante M; Fontenot AP
Clin Immunol; 2006 Nov; 121(2):134-43. PubMed ID: 16697706
[TBL] [Abstract][Full Text] [Related]
15. Genetic susceptibility and immune-mediated destruction in beryllium-induced disease.
Fontenot AP; Maier LA
Trends Immunol; 2005 Oct; 26(10):543-9. PubMed ID: 16099719
[TBL] [Abstract][Full Text] [Related]
16. Beryllium binding to HLA-DP molecule carrying the marker of susceptibility to berylliosis glutamate beta 69.
Amicosante M; Sanarico N; Berretta F; Arroyo J; Lombardi G; Lechler R; Colizzi V; Saltini C
Hum Immunol; 2001 Jul; 62(7):686-93. PubMed ID: 11423174
[TBL] [Abstract][Full Text] [Related]
17. Influence of MHC class II in susceptibility to beryllium sensitization and chronic beryllium disease.
Maier LA; McGrath DS; Sato H; Lympany P; Welsh K; Du Bois R; Silveira L; Fontenot AP; Sawyer RT; Wilcox E; Newman LS
J Immunol; 2003 Dec; 171(12):6910-8. PubMed ID: 14662898
[TBL] [Abstract][Full Text] [Related]
18. Activation pathways implicate anti-HLA-DP and anti-LFA-1 antibodies as lead candidates for intervention in chronic berylliosis.
Chou YK; Edwards DM; Weinberg AD; Vandenbark AA; Kotzin BL; Fontenot AP; Burrows GG
J Immunol; 2005 Apr; 174(7):4316-24. PubMed ID: 15778396
[TBL] [Abstract][Full Text] [Related]
19. Regulatory T cells modulate granulomatous inflammation in an HLA-DP2 transgenic murine model of beryllium-induced disease.
Mack DG; Falta MT; McKee AS; Martin AK; Simonian PL; Crawford F; Gordon T; Mercer RR; Hoover MD; Marrack P; Kappler JW; Tuder RM; Fontenot AP
Proc Natl Acad Sci U S A; 2014 Jun; 111(23):8553-8. PubMed ID: 24912188
[TBL] [Abstract][Full Text] [Related]
20. Role of high-affinity HLA-DP specific CLIP-derived peptides in beryllium binding to the HLA-DPGlu69 berylliosis-associated molecules and presentation to beryllium-sensitized T cells.
Amicosante M; Berretta F; Dweik R; Saltini C
Immunology; 2009 Sep; 128(1 Suppl):e462-70. PubMed ID: 19191908
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
